anti alk2 Search Results


anti alk2  (Boster Bio)
90
Boster Bio anti alk2
Anti Alk2, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+alk2/Anti-ACVR1+%2F+ALK-2+Reference+Antibody/pmc05370018-166-11-13
Average 90 stars, based on 1 article reviews
anti alk2 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
anti-alk2  (Evitria S.A)
90
Evitria S.A anti-alk2
Involvement of <t>ALK2,</t> ALK3 and ALK6 in the effects of AMH in COV434-AMHRII and SKOV3-AMHRII cells. (A) pSMAD1/5 levels were evaluated following incubation with 25 nM LR-AMH for 6 h starting 24 (COV434-AMHRII cells) or 48 (SKOV3-AMHRII cells) h post-transfection with si-ALK2, si-ALK3 and si-ALK6. Data are presented as the mean + max of pSMAD1/5:GAPDH ratios. n=2. (B) Caspase-3/7 activity and cleaved caspase-3 and PARP levels were analyzed following incubation with 25 nM AMH for 6 h (24 and 48 h post-transfection). * P<0.05; ** P<0.01. AMH, anti-Müllerian hormone; LR-AMH, active recombinant AMH; AMHRII, AMH type II receptor; ALK, activin receptor-like kinase; si, small interfering RNA; p, phosphorylated; C., cleaved.
Anti Alk2, supplied by Evitria S.A, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+alk2/anti+alk2/pmc08131086-60-0-10
Average 90 stars, based on 1 article reviews
anti-alk2 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
human activin ria/alk-2 antibody  (Bio-Techne corporation)
92
Bio-Techne corporation human activin ria/alk-2 antibody
Involvement of <t>ALK2,</t> ALK3 and ALK6 in the effects of AMH in COV434-AMHRII and SKOV3-AMHRII cells. (A) pSMAD1/5 levels were evaluated following incubation with 25 nM LR-AMH for 6 h starting 24 (COV434-AMHRII cells) or 48 (SKOV3-AMHRII cells) h post-transfection with si-ALK2, si-ALK3 and si-ALK6. Data are presented as the mean + max of pSMAD1/5:GAPDH ratios. n=2. (B) Caspase-3/7 activity and cleaved caspase-3 and PARP levels were analyzed following incubation with 25 nM AMH for 6 h (24 and 48 h post-transfection). * P<0.05; ** P<0.01. AMH, anti-Müllerian hormone; LR-AMH, active recombinant AMH; AMHRII, AMH type II receptor; ALK, activin receptor-like kinase; si, small interfering RNA; p, phosphorylated; C., cleaved.
Human Activin Ria/Alk 2 Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+alk2/Human+Activin+RIA%2FALK-2+Antibody/bio-techne+corporation___af637
Average 92 stars, based on 1 article reviews
human activin ria/alk-2 antibody - by Bioz Stars, 2026-09
92/100 stars
  Buy from Supplier
rabbit anti-human alk2 / acvr1 (c-terminus)  (RayBiotech)
N/A
ALK2 / ACVR1 Rabbit anti-Human Polyclonal (C-Terminus) (Unconjugated) Antibody, (50 µg)
   Buy from Supplier
mouse monoclonal anti-human alk2  (Angio-Proteomie)
N/A
   Buy from Supplier
goat anti-human alk2 / acvr1 (internal)  (RayBiotech)
N/A
ALK2 / ACVR1 Goat anti-Human Polyclonal (Internal) (Unconjugated) Antibody, (50 µg)
   Buy from Supplier
rabbit anti-human alk2 / acvr1 (aa475-525)  (RayBiotech)
N/A
ALK2 / ACVR1 Rabbit anti-Human Polyclonal (aa475-525) (Unconjugated) Antibody, (50 µg)
   Buy from Supplier
sheep polyclonal anti-human alk2  (Angio-Proteomie)
N/A
   Buy from Supplier
rabbit anti-human alk2 / acvr1 (n-terminus)  (RayBiotech)
N/A
ALK2 / ACVR1 Rabbit anti-Human Polyclonal (N-Terminus) (Unconjugated) Antibody, (50 µg)
   Buy from Supplier
anti alk2  (SignalChem)
N/A
   Buy from Supplier

Image Search Results


Involvement of ALK2, ALK3 and ALK6 in the effects of AMH in COV434-AMHRII and SKOV3-AMHRII cells. (A) pSMAD1/5 levels were evaluated following incubation with 25 nM LR-AMH for 6 h starting 24 (COV434-AMHRII cells) or 48 (SKOV3-AMHRII cells) h post-transfection with si-ALK2, si-ALK3 and si-ALK6. Data are presented as the mean + max of pSMAD1/5:GAPDH ratios. n=2. (B) Caspase-3/7 activity and cleaved caspase-3 and PARP levels were analyzed following incubation with 25 nM AMH for 6 h (24 and 48 h post-transfection). * P<0.05; ** P<0.01. AMH, anti-Müllerian hormone; LR-AMH, active recombinant AMH; AMHRII, AMH type II receptor; ALK, activin receptor-like kinase; si, small interfering RNA; p, phosphorylated; C., cleaved.

Journal: International Journal of Oncology

Article Title: Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival

doi: 10.3892/ijo.2021.5223

Figure Lengend Snippet: Involvement of ALK2, ALK3 and ALK6 in the effects of AMH in COV434-AMHRII and SKOV3-AMHRII cells. (A) pSMAD1/5 levels were evaluated following incubation with 25 nM LR-AMH for 6 h starting 24 (COV434-AMHRII cells) or 48 (SKOV3-AMHRII cells) h post-transfection with si-ALK2, si-ALK3 and si-ALK6. Data are presented as the mean + max of pSMAD1/5:GAPDH ratios. n=2. (B) Caspase-3/7 activity and cleaved caspase-3 and PARP levels were analyzed following incubation with 25 nM AMH for 6 h (24 and 48 h post-transfection). * P<0.05; ** P<0.01. AMH, anti-Müllerian hormone; LR-AMH, active recombinant AMH; AMHRII, AMH type II receptor; ALK, activin receptor-like kinase; si, small interfering RNA; p, phosphorylated; C., cleaved.

Article Snippet: Anti-ALK2 and anti-ALK3 IgG1 and BsAbs were produced in CHO (Evitria AG) and 293T cells (ATCC ® CRL-1573) For antibody production in 293T cells, the cells were cultured in 150 mm 2 dishes to 70% confluence.

Techniques: Incubation, Transfection, Activity Assay, Recombinant, Small Interfering RNA

Incubation with recombinant LR-AMH modulates ALK2 and ALK3 expression in COV434-AMHRII, SKOV3-AMHRII, OVCAR8 and KGN ovarian cancer cells. Immunofluorescence analysis of AMHRII, ALK2, ALK3 and ALK6 expression in basal conditions and after incubation with 25 nM LR-AMH for 90 min. Data are presented as the ratio of receptor (green) and nucleus (blue) labeling. * P<0.05, ** P<0.01 and *** P<0.001 n=6. AMH, anti-Müllerian hormone; LR-AMH, active recombinant AMH; AMHRII, AMH type II receptor; ALK, activin receptor-like kinase; IR, irrelevant antibody; NT, non-treated.

Journal: International Journal of Oncology

Article Title: Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival

doi: 10.3892/ijo.2021.5223

Figure Lengend Snippet: Incubation with recombinant LR-AMH modulates ALK2 and ALK3 expression in COV434-AMHRII, SKOV3-AMHRII, OVCAR8 and KGN ovarian cancer cells. Immunofluorescence analysis of AMHRII, ALK2, ALK3 and ALK6 expression in basal conditions and after incubation with 25 nM LR-AMH for 90 min. Data are presented as the ratio of receptor (green) and nucleus (blue) labeling. * P<0.05, ** P<0.01 and *** P<0.001 n=6. AMH, anti-Müllerian hormone; LR-AMH, active recombinant AMH; AMHRII, AMH type II receptor; ALK, activin receptor-like kinase; IR, irrelevant antibody; NT, non-treated.

Article Snippet: Anti-ALK2 and anti-ALK3 IgG1 and BsAbs were produced in CHO (Evitria AG) and 293T cells (ATCC ® CRL-1573) For antibody production in 293T cells, the cells were cultured in 150 mm 2 dishes to 70% confluence.

Techniques: Incubation, Recombinant, Expressing, Immunofluorescence, Labeling

Differential expression of ALK2 and ALK3 following LR-AMH treatment is associated with the expression of cell survival and apoptosis markers in COV434-AMHRII, SKOV3-AMHRII, OVCAR8 and KGN ovarian cancer cells. Quantification of the western blot analysis of AMH signaling (pSMAD1/5), ALK2 and ALK3 expression, apoptosis induction (cleaved caspase-3 and PARP) and pAKT levels following incubation with 1.6 and 25 nM LR-AMH for 6 h. Data are presented as the fold-change relative to control (no LR-AMH) by bars corresponding from left to right to 0, 1.6 and 25 nM for each protein expression. n>3. Raw data are presented in . AMH, anti-Müllerian hormone; LR-AMH, active recombinant AMH; AMHRII, AMH type II receptor; ALK, activin receptor-like kinase; p, phosphorylated; c, cleaved; PARP, poly(ADP-ribose) polymerase.

Journal: International Journal of Oncology

Article Title: Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival

doi: 10.3892/ijo.2021.5223

Figure Lengend Snippet: Differential expression of ALK2 and ALK3 following LR-AMH treatment is associated with the expression of cell survival and apoptosis markers in COV434-AMHRII, SKOV3-AMHRII, OVCAR8 and KGN ovarian cancer cells. Quantification of the western blot analysis of AMH signaling (pSMAD1/5), ALK2 and ALK3 expression, apoptosis induction (cleaved caspase-3 and PARP) and pAKT levels following incubation with 1.6 and 25 nM LR-AMH for 6 h. Data are presented as the fold-change relative to control (no LR-AMH) by bars corresponding from left to right to 0, 1.6 and 25 nM for each protein expression. n>3. Raw data are presented in . AMH, anti-Müllerian hormone; LR-AMH, active recombinant AMH; AMHRII, AMH type II receptor; ALK, activin receptor-like kinase; p, phosphorylated; c, cleaved; PARP, poly(ADP-ribose) polymerase.

Article Snippet: Anti-ALK2 and anti-ALK3 IgG1 and BsAbs were produced in CHO (Evitria AG) and 293T cells (ATCC ® CRL-1573) For antibody production in 293T cells, the cells were cultured in 150 mm 2 dishes to 70% confluence.

Techniques: Expressing, Western Blot, Incubation, Recombinant

Differential expression of ALK2 and ALK3 following LR-AMH treatment is associated with the expression of cell survival and apoptosis markers in primary ovarian cancer cells. Quantification of the western blot analysis of AMH signaling (pSMAD1/5), ALK2 and ALK3 expression, apoptosis induction (cleaved caspase-3 and PARP) and pAKT levels following incubation of cells isolated from ascites of three patients with ovarian cancer with 1.6 and 25 nM LR-AMH for 6 h. Data are presented as the fold change relative to control (no LR-AMH) by bars corresponding from left to right to 0, 1.6 and 25 nM for each protein expression. n=1 for each patient. Raw data are presented in . AMH, anti-Müllerian hormone; LR-AMH, active recombinant AMH; AMHRII, AMH type II receptor; ALK, activin receptor-like kinase; P, phosphorylated; c, cleaved; PARP, poly(ADP-ribose) polymerase.

Journal: International Journal of Oncology

Article Title: Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival

doi: 10.3892/ijo.2021.5223

Figure Lengend Snippet: Differential expression of ALK2 and ALK3 following LR-AMH treatment is associated with the expression of cell survival and apoptosis markers in primary ovarian cancer cells. Quantification of the western blot analysis of AMH signaling (pSMAD1/5), ALK2 and ALK3 expression, apoptosis induction (cleaved caspase-3 and PARP) and pAKT levels following incubation of cells isolated from ascites of three patients with ovarian cancer with 1.6 and 25 nM LR-AMH for 6 h. Data are presented as the fold change relative to control (no LR-AMH) by bars corresponding from left to right to 0, 1.6 and 25 nM for each protein expression. n=1 for each patient. Raw data are presented in . AMH, anti-Müllerian hormone; LR-AMH, active recombinant AMH; AMHRII, AMH type II receptor; ALK, activin receptor-like kinase; P, phosphorylated; c, cleaved; PARP, poly(ADP-ribose) polymerase.

Article Snippet: Anti-ALK2 and anti-ALK3 IgG1 and BsAbs were produced in CHO (Evitria AG) and 293T cells (ATCC ® CRL-1573) For antibody production in 293T cells, the cells were cultured in 150 mm 2 dishes to 70% confluence.

Techniques: Expressing, Western Blot, Incubation, Isolation, Recombinant

Affinity of the MAbs and BsAbs for their targets estimated by assessing the EC 50 by ELISA.

Journal: International Journal of Oncology

Article Title: Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival

doi: 10.3892/ijo.2021.5223

Figure Lengend Snippet: Affinity of the MAbs and BsAbs for their targets estimated by assessing the EC 50 by ELISA.

Article Snippet: Anti-ALK2 and anti-ALK3 IgG1 and BsAbs were produced in CHO (Evitria AG) and 293T cells (ATCC ® CRL-1573) For antibody production in 293T cells, the cells were cultured in 150 mm 2 dishes to 70% confluence.

Techniques: Enzyme-linked Immunosorbent Assay

The anti-AMHRII-ALK2 BsAb 12G4-2F9 inhibits the growth of COV434-AMHRII cell xenografts in vivo . Nude mice bearing COV434-MISRII cell-derived tumors were treated with 17 mg/kg of anti-AMHRII-CD5 (control BsAb targeting AMHRII and CD5), anti-AMHRII-ALK2 (12G4-2C1 and 12G4-2F9), anti-AMHRII-ALK3 (12G4-3D7 and 12G4-3H6) BsAbs or vehicle (NaCl) twice per week for 4 weeks. Data are presented as the mean ± SEM. * P<0.05 and ** P<0.01. AMHRII, anti-Müllerian hormone type II receptor; ALK, activin receptor-like kinase; BsAbs, bispecific antibodies.

Journal: International Journal of Oncology

Article Title: Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival

doi: 10.3892/ijo.2021.5223

Figure Lengend Snippet: The anti-AMHRII-ALK2 BsAb 12G4-2F9 inhibits the growth of COV434-AMHRII cell xenografts in vivo . Nude mice bearing COV434-MISRII cell-derived tumors were treated with 17 mg/kg of anti-AMHRII-CD5 (control BsAb targeting AMHRII and CD5), anti-AMHRII-ALK2 (12G4-2C1 and 12G4-2F9), anti-AMHRII-ALK3 (12G4-3D7 and 12G4-3H6) BsAbs or vehicle (NaCl) twice per week for 4 weeks. Data are presented as the mean ± SEM. * P<0.05 and ** P<0.01. AMHRII, anti-Müllerian hormone type II receptor; ALK, activin receptor-like kinase; BsAbs, bispecific antibodies.

Article Snippet: Anti-ALK2 and anti-ALK3 IgG1 and BsAbs were produced in CHO (Evitria AG) and 293T cells (ATCC ® CRL-1573) For antibody production in 293T cells, the cells were cultured in 150 mm 2 dishes to 70% confluence.

Techniques: In Vivo, Derivative Assay